Edwards Lifesciences (EW) Revenue — Quarter Ended Dec 31, 2023
Revenue for this quarter rose compared to the previous quarter. It also increased substantially when measured against the same quarter a year earlier.
Key takeaway
Quarter ended Dec 31, 2023 · FY2024 FY
Revenue for this quarter rose compared to the previous quarter. It also increased substantially when measured against the same quarter a year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.3B
Revenue reported for this quarter.
Quarter-over-quarter
+4.6%
Change from the immediately preceding quarter.
Year-over-year
+194.6%
Change from the comparable year-ago quarter.
Trailing four quarters
$5B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2023 | $1.2B | -8.9% |
| Jun 30, 2023 | $1.3B | -4.5% |
| Sep 30, 2023 | $1.2B | -8.2% |
| Dec 31, 2023 | $1.3B | +194.6% |
Revenue performance
The company reported a sequential revenue increase from the immediate prior quarter. On a year-over-year basis, revenue posted a marked improvement.
Quarterly comparison
Revenue growth this quarter outpaced the preceding quarter. The year-over-year comparison also showed a strong gain.
What to watch
Monitor whether the magnitude of year-over-year revenue growth can be sustained in coming quarters.